Conv. Plasma
Nigella Sativa

All bamlanivimab/etesevimab..
Meta analysis
study COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -119% Improvement Relative Risk Hospitalization 52% Progression 20% Bamlanivimab/e..  Delasobera et al.  EARLY TREATMENT Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 438 patients in the USA Lower hospitalization with bamlanivimab/etesevimab (p=0.014) Delasobera et al., Infectious Diseases.., Jan 2022 Favors bamlanivimab/e.. Favors control

Impact of Rapidly Deployed COVID-19 Monoclonal Antibody Infusion Clinics on Rate of Hospitalization

Delasobera et al., Infectious Diseases in Clinical Practice, doi:10.1097/IPC.0000000000001109
Jan 2022  
  Source   PDF   All   Meta
23rd treatment shown to reduce risk in June 2021
*, now known with p = 0.0005 from 17 studies, recognized in 3 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 438 patients in the USA, 253 treated with bamlanivimab, showing significantly lower hospitalization with treatment.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron Haars, Liu, Pochtovyi, Sheward, VanBlargan.
risk of death, 119.4% higher, RR 2.19, p = 0.64, treatment 3 of 253 (1.2%), control 1 of 185 (0.5%).
risk of hospitalization, 52.2% lower, RR 0.48, p = 0.01, treatment 17 of 253 (6.7%), control 26 of 185 (14.1%), NNT 14.
risk of progression, 19.9% lower, RR 0.80, p = 0.52, treatment 23 of 253 (9.1%), control 21 of 185 (11.4%), NNT 44, ER followup visit.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Delasobera et al., 27 Jan 2022, retrospective, USA, peer-reviewed, 12 authors.
This PaperBamlaniv../e..All
Impact of Rapidly Deployed COVID-19 Monoclonal Antibody Infusion Clinics on Rate of Hospitalization
MD Bronson E Delasobera, MD Tara Saggar, MBA Jennifer N Goodwin, MS, PA-C, Amanda Joy, DNP Kiersten N Henry, Acnp-Bc, PharmD, MBA Bonnie Levin, MD David D Hager, MD Joel Mcalduff, PhD Sameer Desale, MHSA Xavier Owens, MD Glenn W Wortmann, MD Princy N Kumar
Background: Providing monoclonal antibody therapy infusions requires challenging logistics, resources, and technology, hindering availability across the United States. Early identification and treatment of COVIDpositive patients can reduce hospitalizations. Objective: This study aimed to describe the referral, selection process, and deployment of outpatient monoclonal infusion clinics, as well as the impact of monoclonal antibody therapy in COVID-positive patients on the rate of emergency department (ED) visits and hospitalization. Methods: This is a retrospective cohort study that used screening of all COVID-positive ambulatory patients using a unique scoring rubric embedded in the emergency medical response for appropriateness for therapy between November 2020 and January 2021. Participants included all outpatients testing positive for COVID-19 were screened, and those eligible were referred for treatment with bamlanivimab. Of the 443 patients referred for treatment, 252 patients were treated with bamlanivimab compared with 191 patients who declined treatment. Patients were treated either in 1 of the 2 outpatient infusion centers (74%) or the ED (26%.) Results: Of 443 patients with positive COVID-19 diagnoses who were eligible for treatment based on a risk assessment rubric, 252 received bamlanivimab. There was a significant reduction in hospitalization of the treatment versus control group (6.7% vs 13.6%, P < 0.05). No significant differences were noted in risk score at screening, ED visits after infusion, days of symptom onset at screening or infusion, or death. Conclusions and Relevance: The efficacy of monoclonal antibody therapy on reducing hospitalization was demonstrated. Rapid development of screening technology, scheduling and operational logistics, and physical space can overcome the challenges in the current environment.
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19, N Engl J Med
Fineberg, Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics, doi:10.17226/26063
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Kumar, Wu, Stosor, Real-world experience of bamlanivimab for COVID-19: a case-control study, Clin Infect Dis, doi:10.1093/cid/ciab305
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19, N Engl J Med
Williamson, Tewarson, Increasing utilization of COVID-19 monoclonal antibodies: considerations and promising practices for states
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop